Skip to main content

Table 3 Therapy, follow-up and administration costs [9, 43,44,45,46,47,48,49,50]

From: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Treatment and posology Ex-factory price (€) per packa Annual monitoring
costs, Year 1 (€)
Annual monitoring
costs, subsequent years (€)
Annual administration costs (€) Source of ex-factory price
Natalizumab – Tysabri, 300 mg, Q4W 1800.00 1104.69 421.42 589.78 Gazette 292, 2006 [9]
Gazette 139, 2014 [43]
IFN beta 1a - Rebif 44 mcg
44mcg, tiw
1027.75 1084.04 399.22 0.00 Gazette 196, 2009 [44]
Gazette 274, 2011 [45]
IFN beta 1b – Betaferon, 250 mcg dieb. alt. 856.01 1084.04 399.22 0.00 Gazette 127, 2000 [46]
Gazette 279, 2007 [47]
Glatiramer acetate – Copaxone, 20 mg, od 769.30 932.51 313.18 0.00 Gazette 106, 2005 [48]
IFN beta 1a – Avonex, 30 mcg, QW 790.17 1084.04 399.22 0.00 Gazette 11, 2004 [49]
Gazette 272, 2011 [50]
  1. Tiw three times a week, dieb. alt every other day, od once daily, QW every week, Q4W every four weeks, IFN interferon
  2. a It does not include temporary law reductions and any discount applied to public structures of Italian NHS